InvestorsHub Logo
Followers 4
Posts 398
Boards Moderated 0
Alias Born 06/21/2006

Re: friendofthedevil post# 3902

Monday, 04/20/2015 4:17:13 PM

Monday, April 20, 2015 4:17:13 PM

Post# of 8529
I should read more carefully before I spend twenty minutes crafting a reply! Just saw this:

ASCO Session
Session titles posted today for next month's ASCO annual meeting included, "High Response Rate and PFS with PEGPH20 added to Nab-Paclitaxel/Gemcitabine in Stage IV Previously Untreated Pancreatic Cancer Patients with High-HA Tumors: Interim Results of a Randomized Phase 2 Study."

I don't get it, frankly, I didn't think ASCO was at all interested in data already presented. And I still think they need to address the "HA status unknown" problem better than what we saw in January.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent HALO News